# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst Silvan Tuerkcan reiterates Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and maintains $2...
Stifel analyst Bradley Canino reiterates Relay Therapeutics (NASDAQ:RLAY) with a Buy and maintains $28 price target.
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price targ...
Relay Therapeutics shares are trading lower by 17.8% during Wednesday's session. The company priced its $200 million offering.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expec...
Relay Therapeutics shares interim data for RLY-2608 from the ReDiscover study, showing a 57% clinical benefit rate. Oppenheimer...